Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Metronidazole Tablets USP 250mg and 500mg (ANDA 203974). The company will commence shipping shortly. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Flagyl Tablets, 250mg and 500mg of GD Searle LLC.
Metronidazole Tablets are used to treat different types of infections which are due to particular types of bacteria and some other infectious organisms, or to prevent infection during an operation. The product has an estimated market size of $58 Million for the twelve months ending March 2015 according to IMS.
This is the 37th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-betalactam products. Aurobindo now has a total of 194 ANDA approvals (167 Final approvals including 9 from Aurolife Pharma LLC and 27 Tentative approvals) from USFDA.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: